TW201713630A - Substituted quinazoline compounds and methods of use thereof - Google Patents

Substituted quinazoline compounds and methods of use thereof

Info

Publication number
TW201713630A
TW201713630A TW105123325A TW105123325A TW201713630A TW 201713630 A TW201713630 A TW 201713630A TW 105123325 A TW105123325 A TW 105123325A TW 105123325 A TW105123325 A TW 105123325A TW 201713630 A TW201713630 A TW 201713630A
Authority
TW
Taiwan
Prior art keywords
methods
compounds
quinazoline compounds
substituted quinazoline
activity
Prior art date
Application number
TW105123325A
Other languages
Chinese (zh)
Inventor
Lian-Sheng Li
Jun Feng
Yun Oliver Long
Yuan Liu
Tao Wu
ping-da Ren
Yi Liu
Original Assignee
Araxes Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JOP/2016/0150A external-priority patent/JOP20160150B1/en
Application filed by Araxes Pharma Llc filed Critical Araxes Pharma Llc
Publication of TW201713630A publication Critical patent/TW201713630A/en

Links

Abstract

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R<SP>2a</SP>, R<SP>2b</SP>, R<SP>2c</SP>, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
TW105123325A 2015-07-22 2016-07-22 Substituted quinazoline compounds and methods of use thereof TW201713630A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195636P 2015-07-22 2015-07-22
US201662342078P 2016-05-26 2016-05-26
JOP/2016/0150A JOP20160150B1 (en) 2015-07-22 2016-07-21 Substituted quinazoline compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
TW201713630A true TW201713630A (en) 2017-04-16

Family

ID=59298009

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105123325A TW201713630A (en) 2015-07-22 2016-07-22 Substituted quinazoline compounds and methods of use thereof

Country Status (1)

Country Link
TW (1) TW201713630A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112225734A (en) * 2019-10-25 2021-01-15 南京瑞捷医药科技有限公司 KRAS G12C inhibitors and uses thereof
CN113015724A (en) * 2018-11-16 2021-06-22 美国安进公司 Improved synthesis of key intermediates of KRAS G12C inhibitor compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113015724A (en) * 2018-11-16 2021-06-22 美国安进公司 Improved synthesis of key intermediates of KRAS G12C inhibitor compounds
CN112225734A (en) * 2019-10-25 2021-01-15 南京瑞捷医药科技有限公司 KRAS G12C inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
MX2019013954A (en) Covalent inhibitors of kras.
MX2018000777A (en) Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins.
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
EA033689B9 (en) Inhibitors of kras g12c
MX2021000887A (en) Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer.
MX2021005924A (en) Compounds and methods of use thereof for treatment of cancer.
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
EA201991884A2 (en) G12C KRAS INHIBITORS
MX2020010484A (en) Substituted heterocyclyl derivatives as cdk inhibitors.
MX2019000536A (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme.
PH12019501639A1 (en) Jaki selective inhibitors
MX2017007607A (en) Inhibitors of cellular necrosis and related methods.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton&#39;s tyrosine kinase
MX2021010297A (en) Human plasma kallikrein inhibitors.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
EA201892098A1 (en) COMPOUND POSSESSING INHIBITING MUTANT IDH ACTIVITY, METHOD FOR PRODUCING AND APPLICATION
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MX2018007511A (en) Alkynyl dihydroquinoline sulfonamide compounds.
BR112018003335A2 (en) pharmaceutical compositions comprising 3- (5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl) -piperidine-2,6-dione
MX2015015290A (en) Furanone compounds as kinase inhibitors.
JOP20160150B1 (en) Substituted quinazoline compounds and methods of use thereof
EA202090268A1 (en) CARBOXAMIDS AS SODIUM CHANNEL MODULATORS
MX2019014773A (en) Ccl2 inhibitors.